FOCUS
A dult spinal deformity (ASD) surgery is associated with significant blood loss, especially when cases involve 3-column osteotomies. 3, 5, [36] [37] [38] Intraoperative blood loss in excess of 4 L has been reported in as many as 24% of patients who have surgery involving 3-column osteotomies. 25 The need for blood transfusions to compensate for these losses is associated with significant complications such as infections, thromboembolic events, and hemolytic transfusion reactions. 8, 12, 13, 19, 20, 33, 34, 39, 41, 46 Patients requiring blood transfusion have been shown to have prolonged hospitalization, increased readmission and reoperation rates, and higher surgery-related costs. 12, 22, 29, 34 Because of these various complications, there have been significant efforts to reduce the need for perioperative blood product transfusion. 7, 14, 16, 23, 24, 28, 47 Utilization of rotational thromboelastometry (ROTEM) for rapid intraoperative evaluation of the coagulation system may allow early detection and management of coagulopathy and thereby reduce blood loss and perioperative transfusion requirements. 21, 24 ROTEM is a dynamic functional hemostatic test based on viscoelastic measurement changes of whole blood during clot formation. 21, 24 Unlike standard laboratory tests (thrombin and prothrombin time and activated partial thromboplastin time), ROTEM can detect abnormalities of the different coagulation pathways such as platelet adhesion/aggregation, coagulation, clot strength, and fibrinolysis with much faster turnaround time. 21, 24 The interaction between coagulation factors and cellular components during the coagulation and subsequent lytic phase can be evaluated and reported in real time. 21 In multiple studies, use of thromboelastometry has been demonstrated to improve profiling of coagulation deficiencies and reduce blood product utilization. However, most of these studies have been restricted to cardiac, trauma, and orthotopic liver transplantation surgery. 11, 17, 27, [30] [31] [32] 35, 40, 42 Few studies suggest ROTEM may have benefits over standard laboratory testing for major spine surgery. 14, 24 However, none have focused on the more complex subset of adult scoliosis cases in which pedicle subtraction osteotomy (PSO) is performed. PSO is a technically challenging technique that is often associated with higher blood loss and morbidity. 1, 3, 5, 37 The objective of this pilot study was to provide a preliminary assessment of ROTEMguided blood product management for patients with ASD undergoing lumbar PSO for deformity correction. We hypothesized that intraoperative ROTEM analysis may allow early identification of intraoperative coagulation deficiencies, and aggressive management may reduce perioperative blood loss and transfusion requirements.
Methods

Patient Selection
This study was approved by the University of Virginia IRB for Health Sciences Research. The requirement for patient informed consent was waived. We performed a retrospective review of a prospectively collected database of patients with ASD (age ≥ 18 years) who underwent single-level lumbar PSO for deformity correction at our institution. Patients who were managed intraoperatively using ROTEM-guided therapy between June 2015 and June 2017 were identified as the ROTEM cohort. Using an institutional database, patients who did not receive intraoperative ROTEM guidance were identified between December 2010 and September 2014 as the historical control cohort. Study inclusion criteria can be summarized as follows: 1) anticipated intraoperative blood loss ≥ 1000 ml; 2) anticipated PSO at one lumbar level; 3) anticipated need for allogeneic blood products; and 4) anticipated postoperative intensive care unit (ICU) admission.
Data Collection
Preoperative baseline demographic data included age, sex, BMI, American Society of Anesthesiologists (ASA) Physical Classification System grade, and history of prior lumbar spine fusion. Preoperative laboratory data included hemoglobin level, platelet count, international normalized ratio (INR), and fibrinogen. These laboratory parameters were also recorded postoperatively (typically ≤ 6 hours after surgery). Surgical data included number of instrumented levels, number of transforaminal lumbar interbody fusions (TLIFs), number of Smith-Petersen osteotomies (SPOs), use of sacropelvic fixation with iliac screws, operative duration, and total dose of intravenous tranexamic acid (TXA).
Outcomes
Co-primary outcomes were intraoperative estimated blood loss (EBL) and total blood product requirements (packed red blood cells [pRBCs] , cryoprecipitate, fresh frozen plasma [FFP] , and platelets). Secondary outcomes were pRBCs (allogeneic and autologous), cryoprecipitate, FFP, platelets transfused during surgery, intraoperative crystalloid and colloid transfusion, postoperative subfascial drain output, days to ambulation, days in the ICU, and length of hospitalization.
Transfusion Algorithm
Our algorithms for intraoperative ROTEM-guided transfusion and point-of-care (POC) or conventional laboratory results-driven blood product management have been previously described in detail. 24 Briefly, ROTEMguided transfusion comprised functional coagulation assessment performed with external temogram (EXTEM) and fibrinogen temogram (FIBTEM) assays. Intraoperative transfusion for temogram abnormalities was protocol-based and directed by a predefined treatment algorithm (Fig. 1A) . Initial ROTEM results were obtained after induction of anesthesia. Then, further intraoperative ROTEM data were obtained after 1-2 units of EBL and at regular intervals at the discretion of the anesthesiologist. Frequency of laboratory testing was at the discretion of the anesthesiologist in POC or conventional laboratory results-driven blood product management (Fig. 1B) . In both algorithms, pRBC transfusions were performed to maintain a hemoglobin level ≥ 9 g/dl.
Intraoperative TXA Administration Protocol
Emerging evidence suggests efficacy of intraopera-tive systemic TXA for reducing blood loss in complex spine surgery. 45, 47 Consequently, our institution has increasingly employed various algorithms for administering TXA during surgery. For this study, all preoperative patients were screened for potential contraindications to intravenous TXA (deep venous thrombosis, pulmonary embolism, stroke, myocardial infarction, cardiac stenting, renal impairment, seizures, or hypercoagulable dis- 24 ROTEM assessment includes EXTEM and FIBTEM assays. Algorithm variables reported by these assays are clotting time (CT), clot formation time (CFT), alpha angle, amplitude at 20 minutes (A20), and maximum clot firmness (MCF). Prolongation of EXTEM CT (> 82 seconds) is related to extrinsic pathway abnormalities (due to functionally low levels of factors II, VII, and X), which is treated with fresh frozen plasma. 43 Low EXTEM A20 and MCF (< 52 mm) indicate poor clot strength, which may be related to either platelet abnormalities (when FIBTEM MCF is normal [7-24 mm] ; treated with platelet transfusion) or low fibrinogen (when FIBTEM MCF is low [≤ 7 mm]; treated with cryoprecipitate transfusion). B: Predefined treatment algorithm for patients receiving intraoperative transfusion therapy guided by conventional or POC testing (recreated from Naik et al.
24
). POC testing for prothrombin time (PT), INR, and platelet count was performed in the blood bank. Assessment of fibrinogen levels was performed via standard laboratory testing. orders). 45, 47 After multidisciplinary discussion (between the attending complex spine surgeon and neuroanesthesiologist), patients who were deemed suitable candidates for intravenous TXA were subject to review of standard hematological laboratory parameters (i.e., platelet count, INR, partial thromboplastin time). After further multidisciplinary assessment, suitable patients were enrolled in our institution's neuroanesthesiology prospective data set for TXA administration. A common intravenous dosing regimen utilized for ROTEM patients was 30 mg/kg loading bolus followed by 5 mg/kg/hr continuous infusion (unless there was a history of thromboembolic events). Lower doses were administered to patients with relative contraindications to systemic TXA. Historically, the thrombotic complication profile of intraoperative TXA administration was unclear; 45 therefore, common intravenous doses for control patients were generally lower (10 mg/kg loading bolus followed by 1 mg/kg/hr continuous infusion). As discussed below, the potential confounding effect of a coagulation-modifying agent such as TXA on assessed study outcomes was controlled using multiple linear regression.
Statistical Analysis
Statistical analyses were performed using SPSS (version 24.0, IBM Corp.) and Stata (version 14.2, StataCorp). Patients who received intraoperative ROTEM-guided therapy (ROTEM cohort) were matched to patients in the historical control cohort treated using the POC or conventional laboratory approach (control cohort). Matching was performed in a 1:1 ratio with a caliper of 0.25, using propensity scores derived from baseline demographic, laboratory, and surgical covariates (age, BMI, revision operation status, number of instrumented levels, number of TLIFs, number of SPOs, and preoperative hemoglobin). In rare cases, blood product transfusion units were recorded without specifying volume; therefore, missing volumes were imputed from volume per unit averages of the entire data set.
Primary and secondary outcomes between the matched groups were then compared. Normality of data in each matched group was assessed using the Shapiro-Wilk test.
Continuous variables were compared using the Student's t-test or Mann-Whitney U-test, as appropriate. Categorical variables were compared using Pearson's chi-square or Fisher's exact tests, as appropriate. These outcomes were then adjusted for residual baseline differences after the matching process using multiple linear regression. Statistical significance was defined as p < 0.05, and all tests were 2-tailed. Due to small sample size, we computed a Cohen's d-based effect size estimation to compare the quantitative strength of ROTEM-based transfusion on primary outcomes. 
Results
Patient Cohort
Intraoperative ROTEM-guided blood product management was utilized during 17 ASD operations that involved single-level lumbar PSO between 2015 and 2017. After performing propensity-score matching using a historical database of patients with PSO who had conventional laboratory testing, the matched cohorts (ROTEM and control) comprised 17 patients each (Fig. 2) . Table 1 compares the baseline characteristics between the matched groups. Between the matched groups, female sex (94% vs 59%, p = 0.04) was more frequent and total intravenous TXA administered (3534.38 ± 2443.90 mg vs 1916.93 ± 1862.77 mg, p = 0.03) was higher in the ROTEM group compared to the control group. Table 2 compares preoperative and initial postoperative laboratory results between matched cohorts. Preoperative and initial postoperative hemoglobin, platelet count, INR, and fibrinogen were comparable between matched cohorts. Table 3 compares the co-primary outcomes between the matched groups. ROTEM patients had less EBL compared to controls, but the difference did not reach significance (3200.00 ± 2106.24 vs 3874.12 ± 2224.22 ml, p = Effect sizes were small to medium (Cohen's d = 0.31) and medium to large (Cohen's d = 0.66) for differences in EBL and total blood product transfusion volume, respectively, between matched groups. Table 4 compares the secondary intraoperative outcomes between the matched groups. Fewer units of pRBCs were transfused in the ROTEM group compared to the control group (3.24 ± 2.68 vs 5.29 ± 3.3, p = 0.048). This difference was no longer significant after adjusting for TXA administration (b = -0.88, 95% CI -3.03 to 1.21, p = 0.39). The transfused pRBC volumes were comparable between the matched groups and remained nonsignificant after adjusting for TXA. The volumes of transfused autologous blood were also comparable between the matched groups and remained nonsignificant after adjusting for TXA.
Comparison of Baseline Characteristics of Matched Groups
Comparison of Co-Primary Outcomes Between Matched Groups
Comparison of Secondary Outcomes Between Matched Groups
More units of cryoprecipitate were transfused in the ROTEM group compared to the control group (1.24 ± 1.20 vs 0.53 ± 1.01, p = 0.03). This remained significant after adjusting for TXA (b = 0.39, 95% CI 0.05 to 1.73, p = 0.04). Volume of cryoprecipitate transfused was higher in the ROTEM group compared to controls (163.88 ± 167.17 ml vs 78.41 ± 149.61 ml, p = 0.04). However, this difference was no longer significant after adjusting for TXA (b = 0.34, 95% CI -13.18 to 229.04, p = 0.08).
Fewer units of FFP were transfused in the ROTEM group compared to the control group (1.29 ± 3.65 vs 3.94 ± 3.29, p < 0.01). However, this difference was no longer significant after adjusting for TXA (b = -0.30, 95% CI -4.92 to 0.48, p = 0.10). Volume of FFP transfused was lower in the ROTEM group compared to controls (119.76 ± 230.82 ml vs 673.06 ± 627.08 ml, p < 0.01). This difference remained significant after adjusting for TXA (b = -0.41, 95% CI -772.55 to -76.30, p = 0.02).
Platelet transfusions (platelet units and volume) were comparable between the matched groups. These remained nonsignificant after adjusting for TXA. Volumes of crystalloid infused were comparable between the matched groups and remained nonsignificant after adjusting for TXA. Volume of colloid infused was higher in the ROTEM group compared to the control group (2329.41 ± 1217.84 ml vs 1411.76 ± 744 ml, p = 0.01), and this remained significant after adjusting for TXA (b = 0.37, 95% CI 23.86 to 1598.08, p = 0.04). Table 5 compares the secondary postoperative outcomes between the matched groups. Postoperative subfascial drain output was reduced in the ROTEM cohort after postoperative day 1 (POD1). After controlling for TXA, drain output remained significantly reduced in the ROTEM cohort after POD2 (Fig. 3) . Total postoperative volumes of blood product transfused were comparable between the two groups. Time to ambulation, length of ICU stay, and time to discharge from hospital were also comparable between the matched groups. Values are expressed as mean ± SD unless otherwise indicated.
Discussion
Surgical management of ASD is often associated with high blood loss and transfusion requirements.
2,4,5,25,36-38 The significant blood loss and transfusions may be related to several factors, such as the relatively advanced age of many patients with ASD, their high rate of associated comorbidities, as well as surgically related factors (i.e., posterior approach, pelvic fixation, osteotomy, and longer operative duration). 26, 42 The need for blood transfusions to compensate for these losses is associated with perioperative complications such as infections, thromboembolic events, and hemolytic transfusion reactions. 8, 12, 13, 19, 20, 33, 34, 39, 41, 46 Also, patients requiring blood transfusion have been shown to have prolonged hospitalization, increased readmission and reoperation rates, and higher surgery-related costs. 12, 22, 29, 34 Because of these various complications, there have been significant efforts to reduce the need for perioperative blood product transfusions. 7, 14, 16, 23, 24, 28, 47 ROTEM analysis may have novel applications in ASD surgery if it allows real-time hematological assessment for rapid correction of intraoperative coagulopathies.
14,24
The utility of ROTEM-guided blood product management has previously been demonstrated in cardiac, trauma, and major abdominal surgery literature. 11, 17, 27, [30] [31] [32] 35, 40, 42 Briefly, ROTEM measures the viscoelastic properties of whole blood. 21 First, a rotating pin is inserted into a cuvette containing citrated whole blood. 21 There is a 1-mm distance between the pin and cuvette, which is bridged by the blood. 24 ROTEM analysis and clot formation begin when calcium and tissue factor are added to mimic the extrinsic coagulation pathway (EXTEM). 21, 24 Initially, there is minimal resistance to pin rotation; however, with increasing clot formation there is increased resistance to rotation, which is detected by an optical sensor. This resistance to rotation is reported in real time as both a functional parameter and a representative curve. 24 In our study, cytochalasin D, a platelet inhibitor, was added to make the results depend on fibrin formation and polymerization alone (FIBTEM). 24 Our ROTEM-based algorithm for blood product transfusion utilized in this study is summarized in Fig. 1A .
There are limited data on the utility of ROTEM in minimizing blood loss and reducing transfusion requirements in ASD surgery. 6, 14, 24 In the first major study on ROTEM and ASD, Naik et al. demonstrated that cryoprecipitate use increased and FFP use decreased in response to ROTEM analysis. 24 These results suggested that ROTEM analysis was able to identify hypofibrinogenemia earlier than conventional lab testing. 24 In patients without TXA administration, Naik et al. also demonstrated that ROTEM analysis could significantly reduce blood loss with a trend toward less pRBC transfusion. 24 In patients with intraoperative TXA administration, there was a nonsignificant reduction in blood loss; however, there was still significantly less FFP and increased cryoprecipitate use in the ROTEM group. 24 In a separate study comparing ROTEM to conventional laboratory testing, Guan et al. demonstrated that ROTEM patients required significantly less total blood products during their hospitalization compared to patients managed with conventional lab testing. 14 Comparison of these prior ROTEM spine studies is limited by differences in ROTEM-transfusion algorithms; most notably, the Guan et al. study algorithm did not administer cryoprecipitate.
6,14
With a significant increase in the number and complexity of ASD corrective surgeries, blood loss often requiring massive intraoperative transfusions becomes a major limiting factor during surgery. 15, 37 This scenario is particularly important during 3-column osteotomies such as the PSO, where extensive intraoperative blood loss may pose a major risk to the patient and prevent execution of the procedure. 1, 3, 5, 37 Neither the Naik et al. nor Guan et al. study focused on this more complex, morbid subset of ASD surgery with PSO.
14,24 Therefore, our study objective was to investigate the effect of ROTEM-guided blood product management on perioperative blood loss and transfusion requirements in patients with ASD undergoing lumbar PSO (often for rigid deformity in revision cases). The preliminary findings of our pilot study are consistent with the prior Naik et al. study. First, cryoprecipitate use was increased and FFP use decreased in response to ROTEM analysis, which we hypothesize is a result of earlier identification of hypofibrinogenemia as a major contributor to ongoing coagulopathy in PSO cases. Next, our results demonstrated a small to medium effect size (Cohen's d = 0.31) on EBL reduction associated with ROTEM analysis. Although there was less EBL in the ROTEM group, this difference was not significant. This lack of significance may be because this pilot retrospective study was likely underpowered, and we hypothesize that further prospec- 
FIG. 3.
Postoperative subfascial drain output was significantly reduced in the ROTEM cohort after POD1. After controlling for TXA administration, drain output remained significantly reduced in the ROTEM cohort after POD2.
tive studies with larger cohorts are necessary to produce more definitive results. The preliminary findings of this pilot study demonstrated that ROTEM analysis was associated with a significant reduction in total blood product transfusion volume. This should be interpreted with caution because this may be confounded by intraoperative TXA administration. Of note, the effect size of ROTEM analysis on total blood product transfusion volume was larger compared to its effect on blood loss. Based on Cohen's d analysis, the effect size for total blood product transfusion between matched cohorts was 0.66, indicating a medium to large effect.
We also sought to determine if ROTEM analysis could have an effect on clinical outcomes. There were no significant differences based on days to ambulation, ICU stay, and length of hospitalization. Again, we believe a larger study cohort is likely needed to demonstrate a significant effect on these clinical outcome parameters. However, our analysis did demonstrate a significant reduction in postoperative subfascial drain output by POD2. This suggests ROTEM analysis may lead to earlier removal of surgical drains and less discomfort for patients during convalescence.
18 Also, this result may suggest ROTEM analysis was indeed beneficial by allowing earlier correction of surgery-related coagulopathy (hypofibrinogenemia), and that the significant effects of blood loss reduction in our study may have been detected postoperatively (by analyzing drain output) rather than intraoperatively with EBL assessment.
It is important to recognize the limitations of the current study. The retrospective, single-center study design utilized in our analysis has inherent limitations. Our results are susceptible to the inherent selection, treatment, and referral biases of our institution and physicians. Also, despite attempts to adjust for baseline differences using multivariable models and propensity-score matching, we acknowledge that a prospective, randomized study would have been a more rigorous and less biased design. It is also important to recognize that a higher total intraoperative dose of TXA was administered to ROTEM patients in this study. This may be attributable to surgeon preference and possible dose-dependent effects. TXA is a coagulation-modifying drug and may confound comparisons of ROTEM versus conventional laboratory testing for blood loss and transfusion reduction. 45 Utilization of systemic TXA (and even topical TXA 10 ) is becoming increasingly common in complex spine surgery. 45, 47 Given the high expected blood loss associated with complex spine operations, 5, 36, 37 it may not be appropriate to design a study withholding TXA until further evidence suggests higher rates of adverse thromboembolic events. 45, 47 Therefore, to control for TXA as a potential confounder, we utilized multiple linear regression when assessing primary and secondary outcomes in our study. However, we acknowledge the potential for nonlinear variability in the pharmacological dose response between patients that would limit this study. Next, because nonsignificant differences in our primary outcomes (after controlling for TXA) may be due to the relatively small study size, we computed a Cohen's d-based effect size estimation to compare the quantitative strength of ROTEM-based transfusion on EBL and total blood product transfusion volume. ROTEM analysis had a small to medium effect size (Cohen's d = 0.31) on EBL and medium to large effect size (Cohen's d = 0.66) on total blood product transfusion volume. These results may support the notion that this pilot retrospective study was likely underpowered, and that small cohort size may account for the lack of statistically significant differences in some assessed outcomes. However, we think our preliminary findings may still benefit other complex spine surgeons and may serve as a baseline to power future, larger prospective ROTEM trials. Finally, this study is limited to a select subset of patients with ASD undergoing a relatively morbid procedure (i.e., lumbar PSO). Surgeries with PSO have high blood loss from bone bleeding, which is further exacerbated in our ASD cohort because of the relatively advanced age of many patients and thin periosteum with wide vascular channels encountered in osteoporotic bone. 5, 37 Although we intended our analysis to focus on this complex ASD subset, our results may not be generalized to less complex, less morbid spine procedures.
Conclusions
For patients with ASD treated with lumbar PSO, more cryoprecipitate and less FFP were transfused in the ROTEM group compared to a control group that utilized conventional lab testing to guide blood product transfusion. Our preliminary findings suggest that ROTEM-guided therapy may allow early identification of hypofibrinogenemia (a major contributor to ongoing coagulopathy), and aggressive management of this may reduce blood loss and total blood product transfusion volume. Future prospective studies with larger cohorts are necessary to identify the appropriate subset of patients with ASD who may benefit from intraoperative ROTEM analysis.
